Helical2
General Information
DCTPep ID DCTPep02759
Peptide Name Helical2
Sequence GLWAIAVKAGKVILKLIVFIWIRV
Sequence Length 24
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Membrane-targeted
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
A549 | Lung adenocarcinoma | EC50>50 µM | MTT assay | 24 h | 1 |
MCF-7 | Invasive breast carcinoma of no special type | EC50>50 µM | MTT assay | 24 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep02759
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C136H224N32O25
Absent amino acids CDEHMNPQSTY
Theoretical pI 11.26
Acidic residues 0
Basic residues 4
Polar residues 2
Molecular weight (Average) 2707.47
Molecular weight (Monoisotopic) 2705.72
Common amino acids I
Net charge 4
Instability index (II) 2.32
Aliphatic index 190.83
Grand average of hydropathicity (GRAVY) 1.671
Half Life
30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 11000
Abs 0.1% (=1 g/l) 4.063
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 31375699
Title In silico design and optimization of selective membranolytic anticancer peptides
Doi 10.1038/s41598-019-47568-9
Year 2019
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available